These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 29167138)

  • 21. Management of ESRD in patients with autosomal dominant polycystic kidney disease.
    Alam A; Perrone RD
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):164-72. PubMed ID: 20219619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease.
    Hoevenaren IA; Wester R; Schrier RW; McFann K; Doctor RB; Drenth JP; Everson GT
    Liver Int; 2008 Feb; 28(2):264-70. PubMed ID: 17927714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
    McEwan P; Bennett Wilton H; Ong ACM; Ørskov B; Sandford R; Scolari F; Cabrera MV; Walz G; O'Reilly K; Robinson P
    BMC Nephrol; 2018 Feb; 19(1):37. PubMed ID: 29439650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autosomal dominant policystic kidney disease, more than a renal disease.
    Torra R
    Minerva Endocrinol; 2014 Jun; 39(2):79-87. PubMed ID: 24736482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
    Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and study protocol of ACQUIRE, a prospective, observational study measuring quality of life, treatment preference and treatment satisfaction of autosomal dominant polycystic kidney disease (ADPKD) patients in Europe.
    Joly D; Quinn J; Mokiou S; O'Reilly K; Sánchez-Covisa J; Wang-Silvanto J; Doll H
    BMC Nephrol; 2020 Jul; 21(1):298. PubMed ID: 32709218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.
    Chebib FT; Perrone RD
    Adv Kidney Dis Health; 2023 May; 30(3):261-284. PubMed ID: 37088528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.
    Hines CB; Hooper GL; Collins-Yoder A
    Nephrol Nurs J; 2020; 47(2):145-150. PubMed ID: 32343088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management.
    Luciano RL; Dahl NK
    Nephrol Dial Transplant; 2014 Feb; 29(2):247-54. PubMed ID: 24215018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan.
    Yen PW; Chen YA; Wang W; Mao FS; Chao CT; Chiang CK; Lin SH; Tarng DC; Chiu YW; Wu MJ; Chen YC; Kao JT; Wu MS; Lin CL; Huang JW; Hung KY
    Nephrology (Carlton); 2024 May; 29(5):245-258. PubMed ID: 38462235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Two cases of autosomal dominant polycystic kidney disease treated with hemodialysis associated with polycystic liver complications related to the cause of death].
    Saima S; Suzuki Y; Yoshimoto K; Nakamura Y; Munakata A
    Nihon Jinzo Gakkai Shi; 1996 Jun; 38(6):278-84. PubMed ID: 8752971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease.
    Fukasawa H; Kaneko M; Niwa H; Yasuda H; Kumagai H; Furuya R
    Nephrology (Carlton); 2018 Mar; 23(3):210-216. PubMed ID: 28024168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autosomal dominant polycystic kidney disease.
    Srivastava A; Patel N
    Am Fam Physician; 2014 Sep; 90(5):303-7. PubMed ID: 25251090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autosomal Dominant Polycystic Kidney Disease: Is There a Role for Autophagy?
    Ponticelli C; Moroni G; Reggiani F
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
    McCarthy S; McMullen M
    ANNA J; 1997 Feb; 24(1):45-51; quiz 52-3. PubMed ID: 9146123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
    Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C
    Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.